Clinical and economic analysis of effectiveness of Nivolumab (Opdivo®) use as second-line monotherapy in adult patients with advanced renal cell carcinoma after previous systemic therapy

M. Yu. Frolov; I. S. Krysanov; V. S. Krysanova

For citations:

Frolov M.Yu., Krysanov I.S., Krysanova V.S. Clinical and economic analysis of effectiveness of Nivolumab (Opdivo®) use as second-line monotherapy in adult patients with advanced renal cell carcinoma after previous systemic therapy. Cancer Urology. 2017;13(1):53-66. (In Russ.) https://doi.org/10.17650/1726-9776-2017-13-1-53-66

This work is licensed under a Creative Commons Attribution 4.0 License.

ISSN 1726-9776 (Print)
ISSN 1996-1812 (Online)

Username
Password
	Remember me
Not a user? Register with this site Forgot your password?

User

Cancer Urology

For citations:

Cookies policy